Wanyama Francis Mugeni, Tauber Rudolf, Mokomba Alfred, Nyongesa Catherine, Blanchard Véronique
Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany.
Clinical Chemistry Unit, Department of Human Pathology, University of Nairobi, P.O. Box 19676, Nairobi 00202, Kenya.
Infect Dis Rep. 2022 Jun 7;14(3):433-445. doi: 10.3390/idr14030047.
Ovarian cancer (OC) is a gynecological malignancy characterized by high morbidity and mortalities due to late-stage diagnosis because accurate early diagnostic biomarkers are lacking. Testing of Hepatitis B virus (HBV), Hepatitis C virus (HCV), and Human immunodeficiency virus (HIV) infections in OC patients is pertinent in light of the emerging evidence of their contribution to poor prognosis. We, for the first time, investigated the prevalence of HBV, HCV, and HIV infections in a Kenyan cohort of OC to inform optimal management. We recruited a cohort of women above 18 years of age, comprising 86 OC patients and 50 healthy controls. Participants' blood samples were serologically screened for HBV, HCV, and HIV. We found seroprevalence rates of 29.1%, 26.7%, and 1.2% for HBV, HIV, and HCV, respectively, in OC patients. The healthy control group had HBV and HIV seroprevalence rates of 3.9% for each with no positive HCV case. HBV/HIV coinfection was noted only in the OC group with a positivity rate of 17.4%. In summary, we found higher HBV and HIV seroprevalence in Kenyan OC patients compared to the healthy control group, whereas HCV prevalence was reflective of the general population. Hence, we recommend screening for HBV and HIV among OC patients destined for anticancer treatment.
卵巢癌（OC）是一种妇科恶性肿瘤，由于缺乏准确的早期诊断生物标志物，晚期诊断导致其发病率和死亡率居高不下。鉴于有新证据表明乙肝病毒（HBV）、丙肝病毒（HCV）和人类免疫缺陷病毒（HIV）感染会导致卵巢癌患者预后不良，对这些感染进行检测具有重要意义。我们首次对肯尼亚一组卵巢癌患者进行了HBV、HCV和HIV感染率调查，以指导优化治疗方案。我们招募了一组18岁以上的女性，包括86名卵巢癌患者和50名健康对照者。对参与者的血液样本进行了HBV、HCV和HIV的血清学筛查。我们发现，卵巢癌患者中HBV、HIV和HCV的血清阳性率分别为29.1%、26.7%和1.2%。健康对照组中HBV和HIV的血清阳性率均为3.9%，没有HCV阳性病例。仅在卵巢癌组中发现了HBV/HIV合并感染，阳性率为17.4%。总之，我们发现肯尼亚卵巢癌患者中HBV和HIV的血清阳性率高于健康对照组，而HCV感染率与普通人群相当。因此，我们建议对准备接受抗癌治疗的卵巢癌患者进行HBV和HIV筛查。
